Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06456580 · ClinicalTrials.gov registry record · Phase 3
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
A Phase 3 study of Generalized Myasthenia Gravis, sponsored by Vor Biopharma.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 180
- Enrollment target
- 20
- Study locations
NCT06456580: Recruiting Phase 3 study of Generalized Myasthenia Gravis, sponsored by Vor Biopharma.
NCT06456580 is a Phase 3 study of Generalized Myasthenia Gravis that is actively recruiting participants, run by Vor Biopharma. The registered enrollment target is 180 participants, above the 124-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (45% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06456580, a Phase 3 study of Generalized Myasthenia Gravis, is actively recruiting participants, sponsored by Vor Biopharma.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 180 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of generalized myasthenia gravis.
Primary Outcome
The MG-ADL is an 8-item patient-reported outcome measure assessing MG symptoms and their effects on daily activities. Each item in the scale is scored on a 0 to 3 (0=normal, 3=severe disease) point scale. The total score is the sum of all individual item scores ranging from 0 to 24. Higher scores indicate more severe disability due to MG. A decrease from Baseline score indicates improvement.
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL Telitacicept
Study Locations (20)
California
- University of Southern California - Los Angeles
- University of California Irvine - Orange
- University of California San Francisco (UCSF) - San Francisco
Florida
- SFM Clinical Research - Boca Raton
- Allied Biomedical Research Institute (ABRI) - Miami
- Medsol Clinical Research Center - Port Charlotte
Kentucky
- University of Kentucky - Lexington
- University of Louisville Physicians - Louisville
Michigan
- Michigan State University Clinical Center - East Lansing
- Trinity Health - Grand Rapids Hospital - Grand Rapids
New York
- Mount Sinai Health System - New York
- Montefiore Medical Center - The Bronx
Texas
- University of Texas Southwestern Medical Center - Dallas
- Houston Methodist Neurological Institute - Houston
Georgia
- Wellstar MCG Health Medical Center - Augusta
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2024-07-17 |
| Est. Completion | 2029-01 |
| Phase | Phase 3 |
What NCT06456580 shows while recruiting
NCT06456580 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, above the 124-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (45% higher).
The record links to 1 condition, with Generalized Myasthenia Gravis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06456580 names 20 study sites across 12 states, led by California, Florida, Kentucky.
Frequently Asked Questions
What is clinical trial NCT06456580 about?
NCT06456580 is a clinical study titled "A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)". The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of generalized myasthenia gravis.
What is the current status of trial NCT06456580?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 180 participants. The study started on 2024-07-17. Estimated completion is 2029-01.
What conditions does trial NCT06456580 study?
This clinical trial studies the following conditions: Generalized Myasthenia Gravis.
What interventions are being tested in trial NCT06456580?
The interventions under investigation include: Placebo (DRUG), Telitacicept (BIOLOGICAL).
Who is sponsoring clinical trial NCT06456580?
This trial is sponsored by Vor Biopharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06456580 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Kansas, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06456580's enrollment target sits among peer trials
180 9th of 26 higher than 17 of 26 other Generalized Myasthenia Gravis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Generalized Myasthenia Gravis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI